Literature DB >> 15985593

Effect of genetic modifiers on cerebral lesions in Fabry disease.

Gheona Altarescu1, David F Moore, Raphael Schiffmann.   

Abstract

Fabry disease is associated with increased risk of premature stroke and presumptive ischemic cerebral lesions. In 57 consecutive patients, 35% of whom had lesions on brain MRI, the authors found that genotypes of polymorphisms G-174C of interleukin-6, G894T of endothelial nitric oxide synthase, factor V G1691A mutation, and the A-13G and G79A of protein Z were all significantly associated with cerebral lesions. These findings suggest that these proteins modulate Fabry cerebral vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985593     DOI: 10.1212/01.WNL.0000166000.24321.4F

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Chronic meningitis and thalamic involvement in a woman: Fabry disease expanding phenotype.

Authors:  Olivier Lidove; Marie-Paule Chauveheid; Ludovic Benoist; Jean-François Alexandra; Isabelle Klein; Thomas Papo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

2.  Association of protein Z and factor VII gene polymorphisms with risk of cerebral hemorrhage: a case-control and a family-based association study in a Chinese Han population.

Authors:  Yi Zeng; Le Zhang; Zhiping Hu; Qidong Yang; Mingming Ma; Baoqiong Liu; Jian Xia; Hongwei Xu; Yunhai Liu; Xiaoping Du
Journal:  J Genet       Date:  2016-06       Impact factor: 1.166

3.  Auditing the frequency and the clinical and economic impact of testing for Fabry disease in patients under the age of 70 with a stroke admitted to Saint Vincent's University Hospital over a 6-month period.

Authors:  J Lambe; I Noone; R Lonergan; N Tubridy
Journal:  Ir J Med Sci       Date:  2017-05-03       Impact factor: 1.568

4.  Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement.

Authors:  Raphael Schiffmann; Amy Rapkiewicz; Mones Abu-Asab; Markus Ries; Hasan Askari; Maria Tsokos; Martha Quezado
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

5.  Aseptic meningitis in Fabry disease due to a novel GLA variant: an expanded phenotype?

Authors:  Paulo Ribeiro Nóbrega; João Lucas Araújo Morais; Alliane Milliane Ferreira; Alisson Dantas de Medeiros; Beatrice Araújo Duarte; Deborah Moreira Rangel; Fabrício Oliveira Lima; Anderson Rodrigues Brandão de Paiva; Luciana Paim-Marques; Fernando Kok; André Luiz Santos Pessoa; Pedro Braga-Neto; Fernanda Martins Maia Carvalho
Journal:  Neurol Sci       Date:  2022-09-12       Impact factor: 3.830

Review 6.  Can we use statins to prevent stroke in Fabry disease?

Authors:  J M Politei
Journal:  J Inherit Metab Dis       Date:  2009-06-02       Impact factor: 4.982

7.  Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.

Authors:  Jarmila Lakomá; Roberto Rimondini; Antonio Ferrer Montiel; Vincenzo Donadio; Rocco Liguori; Marco Caprini
Journal:  Mol Pain       Date:  2016-08-16       Impact factor: 3.395

Review 8.  The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.

Authors:  Valentina Citro; Marco Cammisa; Ludovica Liguori; Chiara Cimmaruta; Jan Lukas; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2016-12-01       Impact factor: 5.923

9.  Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

Authors:  Francesca Scionti; Maria Teresa Di Martino; Simona Sestito; Angela Nicoletti; Francesca Falvo; Katia Roppa; Mariamena Arbitrio; Pietro Hiram Guzzi; Giuseppe Agapito; Antonio Pisani; Eleonora Riccio; Daniela Concolino; Licia Pensabene
Journal:  Oncotarget       Date:  2017-11-18

10.  The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Authors:  Elfrida R Benjamin; Maria Cecilia Della Valle; Xiaoyang Wu; Evan Katz; Farhana Pruthi; Sarah Bond; Benjamin Bronfin; Hadis Williams; Julie Yu; Daniel G Bichet; Dominique P Germain; Roberto Giugliani; Derralynn Hughes; Raphael Schiffmann; William R Wilcox; Robert J Desnick; John Kirk; Jay Barth; Carrolee Barlow; Kenneth J Valenzano; Jeff Castelli; David J Lockhart
Journal:  Genet Med       Date:  2016-09-22       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.